Ideal Cures expands global reach with a presence in America

Appoints Kamlesh Oza as President – Global Business Development

Ideal Cures, an India-based manufacturer of pharmaceutical coatings and excipients for solid oral dosage forms, has opened an office in the US and has appointed Kamlesh Oza as President – Global Business Development.

The firm says the new US office will augment its global reach from an established network in Asia and Europe to the Americas.

Ideal Cures currently has three EXCiPACT certified cGMP manufacturing plants in India, in addition to offices in India, Italy, Spain, Turkey and Israel.

Oza has held various positions at Colorcon in a career of more than 20 years as Managing Director for Colorcon South Asia, General Manager for Film Coatings Globally, General Manager for Brand Enhancement Services and Director of Global Accounts.

In his new role, Oza will start an application lab and manufacturing plant in the US and develop a team of professionals, portfolios and sales strategies.

You may also like

Ingredients

Ideal Cures becomes first Indian company to receive EXCiPACT certification

Sites at Jammu and Khambhat, India, manufacture pharmaceutical excipients according to the EXCiPACT Good Manufacturing Practice (GMP) Certification Standard
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Ingredients

Rousselot and IamFluidics launch dissolvable microcarrier for cell culturing

The alginate and denatured collagen based product allows researchers to produce scalable cell cultures for biologic drugs and cell therapies
Ingredients

Therapeutic: vimseltinib for tenosynovial giant cell tumour

Tenosynovial giant cell tumour (TGCT) is a rare, non-malignant tumour that results from a translocation in the colony stimulating factor 1 (CSF1) gene
Ingredients

Therapeutic: brensocatib for bronchiectasis

The chronic lung disease bronchiectasis is a serious condition in which the bronchi become permanently dilated because of a cycle of infection, inflammation and damage to the lung tissue
Ingredients

Logical Biological expands its raw pharma material development and supply capabilities with new lab

The raw material supplier can now better serve in vitro diagnostic (IVD) manufacturers, as it has a significantly larger operational capacity
Ingredients

Biosynth inaugurates its Biological Technology site in Suzhou, China

The new site will serve the Chinese domestic market, providing raw materials for vaccines and pharmaceuticals, while dealing regional distribution and handling
Subscribe now